Compare · ABT vs GENB
ABT vs GENB
Side-by-side comparison of Abbott Laboratories (ABT) and Generate Biomedicines Inc. (GENB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and GENB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $158.63B, about 96.1x GENB ($1.65B).
- Over the past year, ABT is down 32.2% and GENB is down 0.7% - GENB leads by 31.5 points.
- ABT has been more active in the news (6 items in the past 4 weeks vs 1 for GENB).
- ABT has more recent analyst coverage (25 ratings vs 6 for GENB).
- Company
- Abbott Laboratories
- Generate Biomedicines Inc.
- Price
- $90.44-0.69%
- $12.76-1.62%
- Market cap
- $158.63B
- $1.65B
- 1M return
- +4.00%
- -6.49%
- 1Y return
- -32.20%
- -0.70%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 6
- 1
- Recent ratings
- 25
- 6
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
Latest GENB
- Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SCHEDULE 13G filed by Generate Biomedicines Inc.
- SEC Form SCHEDULE 13G filed by Generate Biomedicines Inc.
- Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
- SEC Form 10-Q filed by Generate Biomedicines Inc.
- Generate Biomedicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- H.C. Wainwright initiated coverage on Generate Biomedicines with a new price target
- Piper Sandler initiated coverage on Generate Biomedicines with a new price target
- Morgan Stanley initiated coverage on Generate Biomedicines with a new price target
- Cantor Fitzgerald initiated coverage on Generate Biomedicines